Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

Karina A. Keogh, Mark Wylam, John H. Stone, Ulrich Specks

Research output: Contribution to journalArticle

363 Citations (Scopus)

Abstract

Objective. To assess the clinical effects of rituximab therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associaied vasculitis (AAV). Methods. The study group comprised 11 patients who had active AAV despite receiving maximally tolerated doses of cyclophosphamide or had contraindications for cyclophosphamide use. All patients had ANCA reactive against proteinase 3. The patients received rituximab infusions and glucocorticoids to induce remission. Three patients also received plasma exchange. No other immunosuppressive agents were used. Glucocorticoids were tapered as soon as control of disease activity was achieved. Disease activity was monitored using the Birmingham Vasculitis Activity Score, modified for Wegener's granulomatosis. Results. Rituximab therapy was well tolerated by all patients, and adverse events were rare. Following the rituximab infusions, circulating B lymphocytes became undetectable, and ANCA titers decreased significantly. Remission was achieved in all patients and was maintained while B lymphocytes were absent. Conclusion. The ability to achieve stable remissions with rituximab in patients with AAV refractory to conventional therapy suggests that B lymphocyte depletion may be a safe, effective, mechanism-based treatment modality for treatment of patients with these conditions.

Original languageEnglish (US)
Pages (from-to)262-268
Number of pages7
JournalArthritis and Rheumatism
Volume52
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Lymphocyte Depletion
Remission Induction
Antineutrophil Cytoplasmic Antibodies
Vasculitis
B-Lymphocytes
Cyclophosphamide
Glucocorticoids
Myeloblastin
Therapeutics
Granulomatosis with Polyangiitis
Plasma Exchange
Maximum Tolerated Dose
Immunosuppressive Agents
Rituximab

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. / Keogh, Karina A.; Wylam, Mark; Stone, John H.; Specks, Ulrich.

In: Arthritis and Rheumatism, Vol. 52, No. 1, 01.2005, p. 262-268.

Research output: Contribution to journalArticle

@article{c2be52f2db8548829efb2c72177e0caa,
title = "Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis",
abstract = "Objective. To assess the clinical effects of rituximab therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associaied vasculitis (AAV). Methods. The study group comprised 11 patients who had active AAV despite receiving maximally tolerated doses of cyclophosphamide or had contraindications for cyclophosphamide use. All patients had ANCA reactive against proteinase 3. The patients received rituximab infusions and glucocorticoids to induce remission. Three patients also received plasma exchange. No other immunosuppressive agents were used. Glucocorticoids were tapered as soon as control of disease activity was achieved. Disease activity was monitored using the Birmingham Vasculitis Activity Score, modified for Wegener's granulomatosis. Results. Rituximab therapy was well tolerated by all patients, and adverse events were rare. Following the rituximab infusions, circulating B lymphocytes became undetectable, and ANCA titers decreased significantly. Remission was achieved in all patients and was maintained while B lymphocytes were absent. Conclusion. The ability to achieve stable remissions with rituximab in patients with AAV refractory to conventional therapy suggests that B lymphocyte depletion may be a safe, effective, mechanism-based treatment modality for treatment of patients with these conditions.",
author = "Keogh, {Karina A.} and Mark Wylam and Stone, {John H.} and Ulrich Specks",
year = "2005",
month = "1",
doi = "10.1002/art.20718",
language = "English (US)",
volume = "52",
pages = "262--268",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

AU - Keogh, Karina A.

AU - Wylam, Mark

AU - Stone, John H.

AU - Specks, Ulrich

PY - 2005/1

Y1 - 2005/1

N2 - Objective. To assess the clinical effects of rituximab therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associaied vasculitis (AAV). Methods. The study group comprised 11 patients who had active AAV despite receiving maximally tolerated doses of cyclophosphamide or had contraindications for cyclophosphamide use. All patients had ANCA reactive against proteinase 3. The patients received rituximab infusions and glucocorticoids to induce remission. Three patients also received plasma exchange. No other immunosuppressive agents were used. Glucocorticoids were tapered as soon as control of disease activity was achieved. Disease activity was monitored using the Birmingham Vasculitis Activity Score, modified for Wegener's granulomatosis. Results. Rituximab therapy was well tolerated by all patients, and adverse events were rare. Following the rituximab infusions, circulating B lymphocytes became undetectable, and ANCA titers decreased significantly. Remission was achieved in all patients and was maintained while B lymphocytes were absent. Conclusion. The ability to achieve stable remissions with rituximab in patients with AAV refractory to conventional therapy suggests that B lymphocyte depletion may be a safe, effective, mechanism-based treatment modality for treatment of patients with these conditions.

AB - Objective. To assess the clinical effects of rituximab therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associaied vasculitis (AAV). Methods. The study group comprised 11 patients who had active AAV despite receiving maximally tolerated doses of cyclophosphamide or had contraindications for cyclophosphamide use. All patients had ANCA reactive against proteinase 3. The patients received rituximab infusions and glucocorticoids to induce remission. Three patients also received plasma exchange. No other immunosuppressive agents were used. Glucocorticoids were tapered as soon as control of disease activity was achieved. Disease activity was monitored using the Birmingham Vasculitis Activity Score, modified for Wegener's granulomatosis. Results. Rituximab therapy was well tolerated by all patients, and adverse events were rare. Following the rituximab infusions, circulating B lymphocytes became undetectable, and ANCA titers decreased significantly. Remission was achieved in all patients and was maintained while B lymphocytes were absent. Conclusion. The ability to achieve stable remissions with rituximab in patients with AAV refractory to conventional therapy suggests that B lymphocyte depletion may be a safe, effective, mechanism-based treatment modality for treatment of patients with these conditions.

UR - http://www.scopus.com/inward/record.url?scp=12344330217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344330217&partnerID=8YFLogxK

U2 - 10.1002/art.20718

DO - 10.1002/art.20718

M3 - Article

VL - 52

SP - 262

EP - 268

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -